Bangbungcau evaluating inavolisib-based combinations sampeuatah
vietnam
Entertainment
+916127027194
frenzinaomi@gmail.com
https://solo.to/ahuds789dushuvs
Added on 21 Mar 2025
2038 Jewell Road
Business Description
These include the INAVO121 trial (NCT05646862), which is evaluating the agent in combination with fulvestrant vs alpelisib (Piqray) plus fulvestrant in hormone receptor–positive, HER2-negative breast cancer following progression on a CDK4/6 inhibitor and endocrine therapy; the INAVO122 study (NCT05894239) investigating inavolisib plus a subcutaneous fixed dose of pertuzumab (Perjeta) and trastuzumab (Herceptin) as maintenance therapy in HER2-positive disease; and the INAVO123 study (NCT06790693) evaluating first-line inavolisib plus a CDK4/6 inhibitor and letrozole in endocrine-sensitive, PIK3CA-mutated hormone receptor–positive, HER2-negative breast cancer.
Additional studies of inavolisib in breast cancer and other tumor types are planned, with the aim of extending the agent’s benefit to more people with PIK3CA-mutated cancers.
Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) has received FDA approval for the treatment of unresectable or metastatic, hormone receptor–positive breast cancer with HER2-low (IHC 1+ or 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) expression, as determined by an FDA-approved test, in patients who have experienced disease progression on 1 or more prior lines of endocrine therapy in the metastatic setting.1
This regulatory decision was supported by findings from the phase 3 DESTINY-Breast06 trial (NCT04494425), in which treatment with T-DXd generated a 36% reduction in the risk of disease progression or death compared with chemotherapy (HR, 0.64; 95% CI, 0.54-0.76; P < .0001) in the overall population of patients with chemotherapy-naive HER2-low -ultralow metastatic breast cancer.1,2 The median progression-free survival (PFS) was 13.2 months (95% CI, 12.0-15.2) with T-DXd vs 8.1 months (95% CI, 7.0-9.0) with chemotherapy. Additionally, the confirmed overall response rate (ORR) was 62.6% with T-DXd compared with 34.4% with chemotherapy.
https://popl.co/card/4OnM8A9Z/1
https://popl.co/card/rcxA2p63/1
https://popl.co/card/1MphZMCo/1
https://popl.co/card/ygt0mqh3/1
https://popl.co/card/kLD9CvnR/1
https://popl.co/card/7eL97C4S/1
https://popl.co/card/tqDhGggd/1
https://popl.co/card/mTNzcv1X/1
https://popl.co/card/GvrEqfxT/1
https://popl.co/card/6gaujg0Y/1
https://papaly.com/categories/share?id=10784e68b176444bb54fc3ff5fa891ab
https://solo.to/ahuds789dushuvs
